SCHEDULE: RA Capital Exits Urogen Pharma Stake

Sentiment:

Schedule 13G Amendment 14 August 2025 6:13 PM

RA Capital Management and its affiliates have fully divested their beneficial ownership in Urogen Pharma Ltd., reporting 0% ownership as of June 30, 2025.

Worse than expectedRA Capital Management and its affiliates, previously significant beneficial owners, now report 0% ownership, indicating a full divestment of their stake in Urogen Pharma Ltd. This is generally viewed as a negative development for the company.

Summary

RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed an Amendment No. 4 to Schedule 13G.
As of June 30, 2025, the Reporting Persons collectively hold 0.00 shares of Urogen Pharma Ltd.'s Ordinary Shares, representing 0.0% of the class.
This filing indicates a complete divestment of their previously held stake in Urogen Pharma Ltd.
The Reporting Persons disclaim status as a "group" for the purposes of this Schedule 13G.

Sentiment

Score: 3

Explanation: The complete divestment by a significant institutional investor like RA Capital Management is typically perceived negatively by the market, signaling a lack of confidence or a strategic exit from the investment.

Negatives

The complete divestment by RA Capital Management and its affiliates, a significant institutional investor, could be perceived as a negative signal regarding Urogen Pharma Ltd.'s future prospects or valuation.

Future Outlook

This filing does not provide any forward-looking statements or guidance from Urogen Pharma Ltd. or the Reporting Persons regarding the issuer's future operations or financial performance.

Industry Context

RA Capital Management is a prominent investment firm focused on the healthcare and life sciences sectors. Their complete exit from a position in a pharmaceutical company like Urogen Pharma Ltd. could reflect a strategic portfolio reallocation, a change in investment thesis regarding the company, or a broader shift in their outlook on the biotech sub-sector Urogen Pharma operates within. Such divestments by significant institutional investors are closely watched by the market as potential indicators of perceived value or risk.

Stakeholder Impact

Shareholders: May react negatively to the news of a major institutional investor exiting their position, potentially leading to downward pressure on the stock price.
RA Capital Management: This filing reflects a completed portfolio adjustment for the investment firm.

Key Dates

Date	Description
06/30/2025	Date of event which requires filing of this statement, reflecting 0% beneficial ownership.
08/14/2025	Date the Schedule 13G/A Amendment No. 4 was signed and filed.

Recommendation

sell

The complete divestment by RA Capital Management, a notable institutional investor, signals a lack of confidence or a strategic shift away from Urogen Pharma Ltd. This could lead to negative market sentiment and downward pressure on the stock price, making it a 'sell' recommendation for investors.

Keywords

Urogen Pharma, RA Capital Management, Schedule 13G, Divestment, Shareholding, Biotech, Pharmaceutical

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.